CD7 CARvac T cell therapy (iCell Gene Therapeutics)

N/A

Report date: 2026/02/26 20:00:22

Base Information

Drug NameCD7 CARvac T cell therapy (iCell Gene Therapeutics)
Drug Alias Nameanti-CD7 CAR T-cell therapy (iCell Gene Therapeutics)chimeric antigen receptor (CAR) immunotherapy directed against the target protein CD7(iCell Gene Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell antigen CD7 inhibitors
TargetsT-cell antigen CD7
Therapy Area/IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesIcell Gene Therapeutics (Int'L) Ltd
China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLCiCar Bio Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A